Jaguar Health, Inc. (JAGX) News
Track canonical SquawkNews coverage tagged to JAGX, Jaguar Health, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 30 indexed stories across 21 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Jaguar Health, Inc. (JAGX) Preliminary SBS-IF Data Accepted for ACG; Phase 2 Readout H2 2027
Jaguar Health said ACG 2026 accepted an abstract on preliminary open-label data for crofelemer in adult SBS-IF. A randomized Phase 2 in adult Type 1 SBS is ongoing, with results expected early H2 2027; an NDA for MVID is
NEWS | Sep 29, 2026, 08:38 AM UTC
L
Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS-IF for crofelemer powder for oral solution, targeting an NDA fili
NEWS | Sep 29, 2026, 08:31 AM UTC
L
Jaguar Health Exchanges 481,584 Shares to Cut $3.4 Million of 2021 Note With Streeterville
Jaguar Health entered into privately negotiated exchange agreements to reduce debt under its 2021 secured promissory note. The company issued 481,584 shares of common stock to Streeterville in exchange for a $3.4 million
EQUITY | Sep 28, 2026, 11:08 AM UTC
L
Weekly Recap: Secondary offering to raise cash and Future Pak U.S. license
Jaguar Health, Inc. (NASDAQ:JAGX) is raising cash via a Sept. 3 secondary offering amid >$25M liabilities and liquidity strain while monetizing U.S. rights to Mytesi and Canalevia-CA1 with a $16M upfront deal with Future
NEWS | Sep 28, 2026, 11:04 AM UTC
L
Jaguar Health Cuts $1.68M From 2021 Note in Stock Exchange With Streeterville
Jaguar Health executed debt-for-equity exchanges with Streeterville to reduce outstanding notes and streamline its capital structure. On September 23, 2026, the company issued 182,091 shares to cut $1,678,320 from its 20
EQUITY | Sep 25, 2026, 10:04 AM UTC
L
Jaguar Health Exchanges 547,898 Shares to Cut 2025 Note Balance by $5.05 Million
Jaguar Health entered into privately negotiated exchange agreements with Streeterville Capital to reduce debt tied to its 2025 Note. In the transaction, the company issued 547,898 common shares in exchange for a $5,049,9
EQUITY | Sep 24, 2026, 10:04 AM UTC
L
JAGX Stock Soars Over 10% Premarket After Best Day In Over 8 Years: What’s Driving The Surge?
Shares of Jaguar Health (JAGX) soared 11% in premarket trading on Wednesday following their best session in over eight years as FDA fee waivers for two drugs and a surge in retail interest put the commercial-stage pharma
REGULATION | Sep 23, 2026, 08:06 AM UTC
L
JAGX - Jaguar Health Receives Fee Waivers from FDA
JAGX - Jaguar Health Receives Fee Waivers from FDA
REGULATION | Sep 22, 2026, 01:05 PM UTC
L
Jaguar Health Announces 1-For-15 Reverse Stk Split >JAGX
Jaguar Health Announces 1-For-15 Reverse Stk Split >JAGX
NEWS | Sep 15, 2026, 01:14 PM UTC
L
Jaguar Health sets 1-for-15 reverse stock split; shares crash
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser
EQUITY | Sep 15, 2026, 01:11 PM UTC
L
JAGX - Jaguar Health, Inc. Announces Reverse Stock Split
JAGX - Jaguar Health, Inc. Announces Reverse Stock Split
EQUITY | Sep 15, 2026, 01:00 PM UTC
L
Jaguar Health patients continue blinded crofelemer extension phase
Jaguar Health said all randomized pediatric patients will continue in the single-blind extension phase of its pivotal crofelemer clinical trial for MVID with intestinal failure (IF). The company said continuation of blin
EQUITY | Sep 10, 2026, 01:01 PM UTC
L
JAGX patients continue crofelemer single-blind extension phase
EQUITY | Sep 10, 2026, 01:00 PM UTC
L
JAGX - Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid B
JAGX - Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
EQUITY | Sep 08, 2026, 01:00 PM UTC
L
Jaguar Health special meeting lacks quorum, no votes taken
Jaguar Health said a special stockholders meeting was convened but lacked a quorum, so no votes were taken.
REGULATION | Sep 04, 2026, 08:24 PM UTC
L
JAGX adds infant patient for compassionate-use Crofelemer in intestinal failure
Jaguar Health says an additional infant patient will receive crofelemer through compassionate use for treatment of intestinal failure.
EQUITY | Sep 04, 2026, 12:30 PM UTC
L
Jaguar Health research note under review
TradingView reports a von First Berlin Equity Research GmbH original-research note on Jaguar Health Inc is under review.
EQUITY | Aug 28, 2026, 12:51 PM UTC
L
Jaguar Health launches Neonorm Dog commercially
Jaguar Health initiated a commercial launch for Neonorm Dog, its non-prescription product for support of normal stool consistency and GI fluid balance in dogs.
EQUITY | Aug 26, 2026, 01:00 PM UTC
L
Jaguar Health reports Q2 2026 results, hosts earnings call
Jaguar Health released second-quarter 2026 financial results and held an earnings call, while highlighting its shift toward rare disease gastrointestinal programs and crofelemer development.
EARNINGS | Aug 19, 2026, 09:18 PM UTC
H
Jaguar Health (JAGX) reports second-quarter 2026 financials
Jaguar Health (JAGX) reports its second-quarter 2026 financials, with the filing and figures available via the referenced release link.
EQUITY | Aug 19, 2026, 08:00 PM UTC
L
JAGX to Hold Investor Webcast Aug. 19 on Q2 2026
Jaguar Health (JAGX) will host an investor webcast on August 19 covering Q2 2026 financials and corporate updates.
EQUITY | Aug 18, 2026, 01:00 PM UTC
H
Jaguar Health Receives $2 Million Payment
Jaguar Health gets $2 million payment from Future Pak
EQUITY | Aug 05, 2026, 01:00 PM UTC
L
JAGX - Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog - C
JAGX - Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog
EQUITY | Jul 28, 2026, 01:00 PM UTC
L
Jaguar Health announces additional infant to receive crofelemer powder
Jaguar Health announces additional infant to receive crofelemer powder
EQUITY | Jul 22, 2026, 01:10 PM UTC
L
JAGX Jaguar health - napo and alivus enter new manufacturing and supply agreement for crofelemer on July 9, 2026 - SEC filing - 2026 agreeme
JAGX Jaguar health - napo and alivus enter new manufacturing and supply agreement for crofelemer on July 9, 2026 - SEC filing - 2026 agreement includes minimum purchase commitment for crofelemer by napo - SEC filing - 20
REGULATION | Jul 14, 2026, 08:16 PM UTC
L
JAGX Converts Preferred Stock
Jaguar Health announces conversion of Series O convertible preferred stock issued as recent one-time stock dividend
EQUITY | Jun 25, 2026, 01:01 PM UTC
M
JAGX Submits FDA Application
Jaguar Health completes submission of new animal drug application for full FDA approval of Crofelemer for treatment of chemotherapy-induced diarrhea in dogs
EQUITY | Jun 23, 2026, 01:02 PM UTC
M
JAGX Reviews Options
Jaguar Health's board initiates process to review strategic options
EQUITY | Jun 22, 2026, 01:55 PM UTC
H
JAGX Reviews Strategic Alternatives
Jaguar Health's board initiates review of strategic alternatives to maximize shareholder value ahead of NDA filing for Crofelemer candidate.
EQUITY | Jun 22, 2026, 01:10 PM UTC
L
JAGX - Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure P
JAGX - Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
EQUITY | Jun 22, 2026, 01:02 PM UTC